[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604859":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":58,"collaborators":60,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":11,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Bioithas SL","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"PROBIOTIC","EXPERIMENTAL",null,[13],"Dietary Supplement: Probiotic - Lacticaseibacillus rhamnosus CRL1505",{"label":15,"type":16,"description":11,"interventionNames":17},"PLACEBO","PLACEBO_COMPARATOR",[18],"Dietary Supplement: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DIETARY_SUPPLEMENT","Probiotic - Lacticaseibacillus rhamnosus CRL1505","The probiotic product is provided in 2g sticks containing the strain Lacticaseibacillus rhamnosus CRL1505 at a concentration of ≥ 1.0E+8 CFU\u002Fg, with corn starch and maltodextrin as excipients.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","The placebo product is provided in 2g sticks of corn starch and maltodextrin.",[15],[30],{"name":31,"affiliation":32,"role":33},"Valentina Taverniti","Microbes & Health R&D Leader, Centro Sperimentale del Latte S.r.l.","STUDY_DIRECTOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":11,"email":39},"Juan Gabriel Agüera Santos","CONTACT","+34623022586","juan.aguera@bioithas.com",[41],{"facility":42,"status":43,"city":44,"state":11,"zip":11,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"MiBioPath Research Group (UCAM)","RECRUITING","Murcia","Spain","ES",{"type":48,"coordinates":49},"Point",[50,51],-1.13004,37.98704,{"lat":51,"lon":50},[54],{"name":55,"role":37,"phone":56,"phoneExt":11,"email":57},"Vicente Navarro López","+34865780170","vicente.navarro@bioithas.com",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR",[61],{"name":62,"class":63},"Centro Sperimentale del Latte S.r.l.","UNKNOWN","100604859","clinical-trial-to-evaluate-the-efficacy-of-lacticaseibacillus-rhamnosus-crl1505-in-the-prevention-of-upper-respiratory-tract-infections-in-children-100604859",false,"NCT07154992","Clinical Trial to Evaluate the Efficacy of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in Children","Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Lacticaseibacillus Rhamnosus CRL1505 in the Prevention of Upper Respiratory Tract Infections in a Healthy Paediatric Population","Inclusion Criteria:\n\n* Healthy children aged 3 to 12 years.\n* Signed Informed Consent by the parents\n\nExclusion Criteria:\n\n* Chronic pathological conditions, such as chronic respiratory diseases (asthma, chronic bronchitis, etc.), chronic heart diseases, chronic neurological diseases (psychomotor impairment, etc.), chronic liver diseases, chronic kidney diseases, chronic gastrointestinal diseases, hematological disorders, etc., or any other disease or condition that the investigator considers to significantly affect the health of the participating child.\n* Metabolic disorders, such as diabetes mellitus, obesity, etc.\n* Immunodeficiency, including HIV infection, chronic corticosteroid treatment, etc.\n* Nasal polyps, nasal ulcers, or other conditions that may cause nasal obstruction.\n* Regular use of medications or dietary supplements that may influence the study outcomes (immunosuppressants\u002Fimmunostimulants, including echinacea supplements, analgesics, anti-inflammatory drugs, antitussives\u002Fexpectorants, flu preparations, decongestants, antibiotics, antihistamines, probiotics, etc.) within the 4 weeks prior to the start of the clinical trial.",true,"ALL","3 Years","12 Years",{"count":76,"type":77},268,"ESTIMATED","INTERVENTIONAL",[80],"NA","Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy paediatric population.",[83,84],"Upper Respiratory Tract Infection","Prevention",[86,87,88,89,90,91],"prevention","upper respiratory tract infections","probiotics","microbiota","microbiome","children","2025-09-08",{"date":94,"type":95},"2025-09-12","ACTUAL",{"date":97,"type":95},"2024-12-17",{"date":99,"type":77},"2027-04",{"name":5,"class":6},1]